Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPM6690176 in RAS-mutant Metastatic Colorectal Cancer
NCT07391566Phase 2Not yet recruiting
- Sponsor
- Luye Pharma Group
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LY01024 in metastatic colorectal cancer (mCRC), sponsored by Luye Pharma Group. Primary endpoints: Dose-limiting toxicities at 28 days, Maximum tolerated dose at 28 days and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
LY01024
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07391566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391566.